Regulatory Information
AGUETTANT ASIA PACIFIC PTE. LTD.
AGUETTANT ASIA PACIFIC PTE. LTD.
Therapeutic
Prescription Only
Formulation Information
INJECTION, SOLUTION
**4.2. Dosage and method of administration** _Adults and the elderly_ Up to 30 mg in increments of 3 – 7.5 mg. After the development of hypotension, by slow intravenous administration. _Paediatric Population_ 0.5 – 0.75 mg/kg body weight or 17 – 25 mg/m2 body surface. After the development of hypotension, by slow intravenous administration. **Compatibilities** Ephedrine is reported to be compatible with 0.9% sodium chloride.
INTRAVENOUS
Medical Information
**4.1. Therapeutic indications** Reversal of anaesthesia induced hypotension during spinal and epidural anaesthesia
**4.3. Contraindications** This medicinal product must never be used in the following cases: - hypersensitivity to the active substance or to any of the excipients listed in section 6.1 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_. - in combination with other indirect sympathomimetic agents such as pseudoephedrine, methylphenidate, bupropion, cafedrine, and theodrenaline. - in combination with alpha sympathomimetic agents. - in combination with irreversible monoamine oxidase inhibitors (MAOI).
C01CA26
ephedrine
Manufacturer Information
AGUETTANT ASIA PACIFIC PTE. LTD.
Laboratoire Aguettant
Laboratoire AGUETTANT
Active Ingredients
Documents
Package Inserts
Ephedrine Aguettant PFS (30mg in 10ml) PI.pdf
Approved: August 25, 2023